Literature DB >> 31515252

Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period.

Gunnar Juliusson1,2, Oskar Hagberg3, Vladimir Lj Lazarevic1, Emma Ölander4, Petar Antunovic5, Jörg Cammenga6, Lovisa Wennström7, Lars Möllgård7, Mats Brune7, Martin Jädersten8, Stefan Deneberg8, Sören Lehmann8,9, Åsa Rangert Derolf8, Martin Höglund9,10.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31515252      PMCID： PMC6839949          DOI： 10.1182/blood.2019001728

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  15 in total

1.  Sex Differences in Efficacy and Toxicity of Systemic Treatments: An Undervalued Issue in the Era of Precision Oncology.

Authors:  Berna C Özdemir; Chantal Csajka; Gian-Paolo Dotto; Anna Dorothea Wagner
Journal:  J Clin Oncol       Date:  2018-07-13       Impact factor: 44.544

2.  Sex differences in cancer risk and survival: A Swedish cohort study.

Authors:  Cecilia Radkiewicz; Anna L V Johansson; Paul W Dickman; Mats Lambe; Gustaf Edgren
Journal:  Eur J Cancer       Date:  2017-08-10       Impact factor: 9.162

Review 3.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

4.  Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia.

Authors:  J W Yates; H J Wallace; R R Ellison; J F Holland
Journal:  Cancer Chemother Rep       Date:  1973 Nov-Dec

5.  Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories.

Authors:  Kyle J Foreman; Neal Marquez; Andrew Dolgert; Kai Fukutaki; Nancy Fullman; Madeline McGaughey; Martin A Pletcher; Amanda E Smith; Kendrick Tang; Chun-Wei Yuan; Jonathan C Brown; Joseph Friedman; Jiawei He; Kyle R Heuton; Mollie Holmberg; Disha J Patel; Patrick Reidy; Austin Carter; Kelly Cercy; Abigail Chapin; Dirk Douwes-Schultz; Tahvi Frank; Falko Goettsch; Patrick Y Liu; Vishnu Nandakumar; Marissa B Reitsma; Vince Reuter; Nafis Sadat; Reed J D Sorensen; Vinay Srinivasan; Rachel L Updike; Hunter York; Alan D Lopez; Rafael Lozano; Stephen S Lim; Ali H Mokdad; Stein Emil Vollset; Christopher J L Murray
Journal:  Lancet       Date:  2018-10-16       Impact factor: 79.321

6.  Sex disparity in childhood and young adult acute myeloid leukemia (AML) survival: Evidence from US population data.

Authors:  Md Jobayer Hossain; Li Xie
Journal:  Cancer Epidemiol       Date:  2015-11-09       Impact factor: 2.984

7.  Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

Authors:  Gunnar Juliusson; Petar Antunovic; Asa Derolf; Sören Lehmann; Lars Möllgård; Dick Stockelberg; Ulf Tidefelt; Anders Wahlin; Martin Höglund
Journal:  Blood       Date:  2008-11-13       Impact factor: 22.113

8.  Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017.

Authors: 
Journal:  Lancet       Date:  2018-11-08       Impact factor: 79.321

9.  Why is the gender gap in life expectancy decreasing? The impact of age- and cause-specific mortality in Sweden 1997-2014.

Authors:  Louise Sundberg; Neda Agahi; Johan Fritzell; Stefan Fors
Journal:  Int J Public Health       Date:  2018-04-13       Impact factor: 3.380

Review 10.  Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.

Authors:  Andrew H Wei; Ing S Tiong
Journal:  Blood       Date:  2017-10-19       Impact factor: 25.476
View more
  12 in total

1.  Impact of treatment delay in acute myeloid leukemia revisited.

Authors:  Gunnar Juliusson; Oskar Hagberg; Vladimir Lj Lazarevic; Sören Lehmann; Martin Höglund
Journal:  Blood Adv       Date:  2021-02-09

2.  Hypo, Hyper, or Combo: new paradigm for treatment of acute myeloid leukemia in older people.

Authors:  Gunnar Juliusson; Martin Höglund; Sören Lehmann
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

3.  DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia.

Authors:  Xueqian Li; Jiaqian Qi; Xiaofei Song; Xiaoyan Xu; Tingting Pan; Hong Wang; Jingyi Yang; Yue Han
Journal:  Exp Hematol Oncol       Date:  2022-10-18

4.  The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting.

Authors:  Gunnar Juliusson; Martin Jädersten; Stefan Deneberg; Sören Lehmann; Lars Möllgård; Lovisa Wennström; Petar Antunovic; Jörg Cammenga; Fryderyk Lorenz; Emma Ölander; Vladimir Lj Lazarevic; Martin Höglund
Journal:  Blood Adv       Date:  2020-03-24

Review 5.  How old is too old for a transplant?

Authors:  Daniel Weisdorf
Journal:  Best Pract Res Clin Haematol       Date:  2021-01-12       Impact factor: 3.020

6.  Associations between complete remission and 2- to 3-year survival following 7 + 3 induction for acute myeloid leukemia.

Authors:  Megan Othus; Guillermo Garcia-Manero; John Godwin; James Weick; Derek Stirewalt; Frederick Appelbaum; Harry Erba; Elihu Estey
Journal:  Leuk Lymphoma       Date:  2021-03-10

Review 7.  A precision medicine approach to management of acute myeloid leukemia in older adults.

Authors:  Shristi Upadhyay Banskota; Nabin Khanal; Vijaya Raj Bhatt
Journal:  Curr Opin Oncol       Date:  2020-11       Impact factor: 3.915

Review 8.  Determination of fitness and therapeutic options in older patients with acute myeloid leukemia.

Authors:  Jorge E Cortes; Priyanka Mehta
Journal:  Am J Hematol       Date:  2021-01-12       Impact factor: 10.047

9.  Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?

Authors:  David Martínez-Cuadrón; Josefina Serrano; Cristina Gil; Mar Tormo; Pilar Martínez-Sánchez; José A Pérez-Simón; Raimundo García-Boyero; Carlos Rodríguez-Medina; María López-Pavía; Celina Benavente; Juan Bergua; Esperanza Lavilla-Rubira; María L Amigo; Pilar Herrera; Juan M Alonso-Domínguez; Teresa Bernal; Mercedes Colorado; María J Sayas; Lorenzo Algarra; María B Vidriales; Gabriela Rodríguez-Macías; Susana Vives; Manuel M Pérez-Encinas; Aurelio López; Víctor Noriega; María García-Fortes; Fernando Ramos; Juan I Rodríguez-Gutiérrez; Lisette Costilla-Barriga; Jorge Labrador; Blanca Boluda; Rebeca Rodríguez-Veiga; Joaquín Martínez-López; Miguel A Sanz; Pau Montesinos
Journal:  Leukemia       Date:  2020-10-19       Impact factor: 11.528

Review 10.  BiTEs, DARTS, BiKEs and TriKEs-Are Antibody Based Therapies Changing the Future Treatment of AML?

Authors:  Cecily Allen; Amer M Zeidan; Jan Philipp Bewersdorf
Journal:  Life (Basel)       Date:  2021-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.